Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Niagen Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Niagen Bioscience's position in the market.
Niagen Bioscience (NASDAQ: NAGE) has confirmed its operational resilience amid new tariff developments, highlighting that its flagship Niagen® ingredient remains exempt from recent tariffs. The company's primary product, nicotinamide riboside (NR), is manufactured, encapsulated, and bottled entirely in the United States through partner W.R. Grace.
With only a minimal portion of materials sourced internationally, the company's manufacturing costs remain largely protected from global price volatility. In 2024, 24% of the company's revenue came from international sales, with 12% specifically from A.S. Watson in Hong Kong, a duty-free market unaffected by tariffs.
Niagen Bioscience (NASDAQ: NAGE) has confirmed that its operations remain unaffected by recent global tariffs, primarily due to its U.S.-based manufacturing strategy. The company's flagship product Niagen® (patented nicotinamide riboside) is manufactured, encapsulated, and bottled domestically by partner W.R. Grace.
The company's strategic decision to maintain a U.S.-based supply chain has proven beneficial, with only a minimal portion of materials sourced internationally. Additionally, nicotinamide riboside (NR) currently maintains an exempt status from recent tariffs, allowing uninterrupted international operations.
In 2024, 24% of the company's revenue came from international sales, with 12% specifically from A.S. Watson in Hong Kong, a duty-free market unaffected by tariffs. The company expects to maintain current costs, pricing, and product delivery capabilities.
Niagen Bioscience (NASDAQ: NAGE) has secured U.S. Patent 12,252,506 for nicotinamide riboside (NR) salt forms, strengthening its NAD+ precursor intellectual property portfolio. The composition of matter patent, exclusively licensed from Queen's University Belfast, covers various NR salt forms including NR Malate and NR Tartrate, as well as other derivatives.
The patent grants Niagen exclusive rights for different NR salt forms and manufacturing methods until 2034. The company's IP portfolio now includes over 90 patents related to its flagship Niagen® ingredient, positioning it as a leader in NAD+ precursor development. According to CEO Rob Fried, any company developing products using these NR salt forms would infringe on this patent.
The protected salt forms include carboxylic acid, dicarboxylic acid, aminodicarboxylic acid, phosphate, sulfate, carbonate, and carbamate salts for nutritional supplement use. Niagen Bioscience claims to be the only company capable of producing NR and its salt forms at commercial scale without patent violation.
Niagen Bioscience, Inc. (Nasdaq: NAGE), formerly ChromaDex Corp., announced its corporate rebranding and new ticker symbol effective March 19, 2025. The company, a global authority on NAD+ with over 25 years of legacy, focuses on healthy aging through its flagship product Niagen, a patented nicotinamide riboside (NR) ingredient.
The company reported strong financial performance with full-year 2024 net sales of $99.6 million, up 19% year-over-year, and maintains $44.7 million in cash with no debt. Their product portfolio includes Tru Niagen, the #1 NAD+ boosting oral supplement in the US, and Niagen Plus, a pharmaceutical-grade IV and injectable version available by prescription at 475 clinics nationwide.
The rebranding reflects the company's evolution and success in NAD+ research, supported by over 35 human clinical studies on Niagen. The executive team will commemorate this milestone at the Nasdaq Closing Bell Ceremony on March 19, 2025.
